A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain.
A Markov model was constructed to simulate the resource use and health outcomes of one year of treatment comparing the fentanyl transdermal therapeutic system (fentanyl-TTS) with oral sustained-release (SR) morphine in outpatients with noncancer pain in Denmark. Effectiveness was assessed in terms of days of good pain control and days on initial treatment. Costs included those of baseline pain management, including breakthrough pain; co-medication costs; and control of adverse events. Fentanyl-TTS was more effective than SR-morphine in achieving good pain control (99 vs. 64 days, respectively) and the incremental cost-effectiveness of fentanyl-TTS was US dollars 10.26 per extra day of good pain control. Patients treated with fentanyl-TTS remained considerably longer on initial treatment compared with those treated with SR-morphine (166 days vs. 117 days, respectively). The results of this study suggest that fentanyl-TTS is a competitive therapeutic and economic choice for the treatment of chronic noncancer pain.
Frei
Andreas
A
HealthEcon, Basle, Switzerland. afrei@healthecon.com
Andersen
Steen
S
Hole
Peter
P
Jensen
Niels-Henrik
NH
D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003692:Delayed-Action Preparations; D003718:Denmark; D017850:Economics, Pharmaceutical; D005283:Fentanyl / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009020:Morphine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D009020:Morphine; D005283:Fentanyl